These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26700310)

  • 1. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
    Wu W; Ma D; Wang P; Cao L; Lu T; Fang Q; Zhao J; Wang J
    FEBS J; 2016 Mar; 283(5):834-49. PubMed ID: 26700310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes multiple myeloma resistance through the JAK2/STAT3 pathway.
    Huang J; Huang LQ; He HS; Yan J; Huang C; Wang R; Guan Y; Huang DP
    Life Sci; 2020 Sep; 257():118088. PubMed ID: 32663573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
    Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
    Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
    Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
    Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.
    Zhang Z; Wang W; Ma D; Xiong J; Kuang X; Zhang S; Fang Q; Wang J
    Aging (Albany NY); 2020 Apr; 12(8):6611-6629. PubMed ID: 32298237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
    Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
    Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
    Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
    Alas S; Bonavida B
    Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
    Barrera LN; Rushworth SA; Bowles KM; MacEwan DJ
    Cell Cycle; 2012 Jun; 11(12):2248-52. PubMed ID: 22617388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
    Kawano Y; Fujiwara S; Wada N; Izaki M; Yuki H; Okuno Y; Iyama K; Yamasaki H; Sakai A; Mitsuya H; Hata H
    Int J Oncol; 2012 Sep; 41(3):876-84. PubMed ID: 22766978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
    Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
    Kim SH; Ahn KS; Jeong SJ; Kwon TR; Jung JH; Yun SM; Han I; Lee SG; Kim DK; Kang M; Chen CY; Lee JW; Kim SH
    Eur J Pharmacol; 2011 Mar; 654(1):10-6. PubMed ID: 21172343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
    de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
    Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. As
    Wu D; Dong W; Fang K; Wang M
    Technol Cancer Res Treat; 2019; 18():1533033819896806. PubMed ID: 31868118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy.
    Tan Q; Wang H; Hu Y; Hu M; Li X; Aodengqimuge ; Ma Y; Wei C; Song L
    Cancer Sci; 2015 Aug; 106(8):1023-32. PubMed ID: 26041409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
    Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC
    Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
    Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
    Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
    Liu Y; Liu A; Li H; Li C; Lin J
    Cancer Prev Res (Phila); 2011 Aug; 4(8):1296-305. PubMed ID: 21490132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. cAMP/PKA enhances interleukin-1β-induced interleukin-6 synthesis through STAT3 in glial cells.
    Tanabe K; Kozawa O; Iida H
    Cell Signal; 2016 Jan; 28(1):19-24. PubMed ID: 26527061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
    Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
    Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.